The company's only commercial product is the Moderna COVID-19 vaccine.
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2023 rankings JUST Capital asked a representative sample of 3,002 Americans to compare 20 different business Issues on a head-to-head basis, producing a reliable hierarchy of Issues ranked in order of priority. Issues are organised under the headings Workers, Customers, Communities, the Environment, or Shareholders & Governance. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 190th of 951 companies, and 11th of 41 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2023)
In February 2016, a Nature editorial criticised Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed Theranos.
Source: Nature (2016)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
This company has responsibility claims on its website under the headings Medicines for Patients, Employees, Environment, Community, Governance & Ethics, CSR Policies & Data.
Source: company website (2021)
This company received an S&P Global ESG Score of 50/100 in the Biotechnology category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 23 Sep 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022)
|Revenue||803 million USD (2020)|